These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 30684076)

  • 21. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
    Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
    Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
    Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
    BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
    Sattar N; Fitchett D; Hantel S; George JT; Zinman B
    Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
    Riggs MM; Seman LJ; Staab A; MacGregor TR; Gillespie W; Gastonguay MR; Woerle HJ; Macha S
    Br J Clin Pharmacol; 2014 Dec; 78(6):1407-18. PubMed ID: 24964723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    Ferrannini E; Muscelli E; Frascerra S; Baldi S; Mari A; Heise T; Broedl UC; Woerle HJ
    J Clin Invest; 2014 Feb; 124(2):499-508. PubMed ID: 24463454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
    Fujimori N; Tanaka N; Kimura T; Sano K; Horiuchi A; Kato N; Takahashi Y; Kuribayashi N; Sugiura A; Yamazaki T; Joshita S; Umemura T; Matsumoto A; Tanaka E
    Clin J Gastroenterol; 2020 Feb; 13(1):83-89. PubMed ID: 31292843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Sep; 63(18):2491-2497. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.